InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

Current share price for RAP : $0.030 0.002 (7.14%)+

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$12 SleepCheck Launched on Select Android Devices 29 Dec 2020 9:14AM $0.080 $0.030 fallen by 62.50%
$12 ResApp Terminates MOU with RB 23 Dec 2020 9:25AM $0.083 $0.030 fallen by 63.86%
$12 Software updates for ResAppDx to underpin growth 22 Dec 2020 9:32AM $0.083 $0.030 fallen by 63.86%
$12 S&P DJI Announces December 2020 Quarterly Rebalance 11 Dec 2020 5:10PM $0.089 $0.030 fallen by 66.29%
$12 Appointment of Joint Company Secretary 4 Dec 2020 10:47AM $0.090 $0.030 fallen by 66.67%
$12 Change of Director's Interest Notice 2 Dec 2020 5:53PM $0.090 $0.030 fallen by 66.67%
$12 Appendix 3G 2 Dec 2020 5:42PM $0.090 $0.030 fallen by 66.67%
$12 Notification of Change of Auditor 26 Nov 2020 7:54PM $0.090 $0.030 fallen by 66.67%
$12 Adoption of New Constitution 26 Nov 2020 7:50PM $0.090 $0.030 fallen by 66.67%
$12 Results of Annual General Meeting 26 Nov 2020 7:09PM $0.090 $0.030 fallen by 66.67%
$12 Annual General Meeting Presentation 26 Nov 2020 3:40PM $0.090 $0.030 fallen by 66.67%
$12 2020 Letter to Shareholders 26 Nov 2020 9:44AM $0.091 $0.030 fallen by 67.03%
$12 Positive engagement with US FDA following SleepCheck Pre-Sub 24 Nov 2020 9:19AM $0.091 $0.030 fallen by 67.03%
$12 ResAppDx to be integrated into WMA telehealth application 19 Nov 2020 9:50AM $0.090 $0.030 fallen by 66.67%
$12 Medgate to pilot ResAppDx for telehealth across Europe 9 Nov 2020 9:18AM $0.086 $0.030 fallen by 65.12%
$12 Quarterly Activities Report and Appendix 4C 30 Oct 2020 9:25AM $0.110 $0.030 fallen by 72.73%
$12 ResAppDx launched on select Android devices 28 Oct 2020 9:59AM $0.105 $0.030 fallen by 71.43%
$12 Quarterly Results and Investor Conference Call Notification 27 Oct 2020 9:16AM $0.110 $0.030 fallen by 72.73%
$12 Notice of Annual General Meeting/Proxy Form 26 Oct 2020 1:44PM $0.115 $0.030 fallen by 73.91%
$12 AstraZeneca to use new ResApp software in study - Revised 22 Oct 2020 10:45AM $0.105 $0.030 fallen by 71.43%
$12 Pause in Trading 22 Oct 2020 9:58AM $0.105 $0.030 fallen by 71.43%
$12 AstraZeneca to use new ResApp software in clinical study 22 Oct 2020 9:31AM $0.105 $0.030 fallen by 71.43%
$12 Partners with largest Australian consumer healthcare network 21 Oct 2020 9:19AM $0.100 $0.030 fallen by 70%
$12 ResApp Partners with Diabetes Queensland for SleepCheck 28 Sep 2020 9:04AM $0.105 $0.030 fallen by 71.43%
$12 Section 708A Notice and Appendix 2A 22 Sep 2020 4:55PM $0.105 $0.030 fallen by 71.43%

201 - 225 of 573 results

Page 9 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.